<DOC>
	<DOCNO>NCT00280215</DOCNO>
	<brief_summary>This study test effectiveness two medication : ACEI ( angiotensin convert enzyme inhibitor ) ARB ( angiotensin receptor blocker ) reduce renal injury induce hyperoxaluria patient Primary Hyperoxaluria . Hypothesis : Calcium oxalate crystal deposition kidney cause inflammation result injury kidney tissue . Angiotensin blockade improve change , thus slow progression renal insufficiency patient Primary Hyperoxaluria .</brief_summary>
	<brief_title>Renal Protective Effect ACEI ARB Primary Hyperoxaluria</brief_title>
	<detailed_description>In patient primary hyperoxaluria ( PH ) , deficiency hepatic enzyme important disposition glyoxylate result mark hyperoxaluria . Calcium oxalate crystal high oxalate concentration renal filtrate result inflammation injury renal parenchyma . Loss renal function time characteristic , end stage renal failure occur half patient age 35 year , early infancy patient . Experience animal model hyperoxaluria , renal disease , support role ACEI ARB medication ameliorate inflammation injury thus provide renal protective effect . We propose study short-term effect combine angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor block ( ARB ) therapy patient PH , control , randomize , two-year study . Primary endpoint urinary marker renal tubular injury ( retinol binding protein ( RBP ) , alpha 1 microglobulin ( α1m ) , γ-glutamyl transferase ( GGT ) ) interstitial fibrosis ( transform growth factor beta 1 ( TGFβ1 ) . Secondary endpoint rate change renal tubular injury renal function determine serum creatinine creatinine clearance .</detailed_description>
	<mesh_term>Hyperoxaluria , Primary</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Lisinopril</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Diagnosis PH establish liver enzyme analysis patient affect sibling , DNA test mutation AGXT GR/HPR gene , meet clinical criterion ( Urine oxalate &gt; 70 mg/1.73 m2/day absence malabsorption dietary excess oxalate . Elevated urine glycolate glycerate provide support evidence type I type II PH , respectively ) . 2 . Hyperoxaluria persist treatment pyridoxine . 3 . Ten year age old . 4 . Glomerular filtration rate &gt; 50 ml/min/1.73 m2 start study . 5 . Women child bear age require use adequate contraception 3 month throughout study . 6 . Patients stable program pyridoxine , neutral phosphate , citrate medication . Age &lt; 10 year . b. Glomerular filtration rate &lt; 50 start study c. Hypersensitivity ACEI ARB medication d. Chronic use ACEI ARB medication prior enrollment e. Hyperkalemia f. Previous renal transplant g. Homozygosity G170R mutation AGXT h. Unwillingness use adequate contraception study . i. Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Primary Hyperoxaluria</keyword>
</DOC>